key: cord-0964885-euudzrgv authors: León, Fabiola Justina Fumero; da Silva, Lucas Lima; Santos, Alanna Calheiros; Duarte da Costa, Vanessa; Miguel, Juliana Custódio; Marques, Julia Trece; Nascimento, Giselle Prado; Ferreira da Silva, Elisangela; Lewis‐Ximenez, Lia Laura; Villar, Livia Melo; de Paula, Vanessa Salete title: Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and hepatitis C virus date: 2022-02-04 journal: J Med Virol DOI: 10.1002/jmv.27614 sha: f054708962fa12dbb7b035778e745fa660fa8695 doc_id: 964885 cord_uid: euudzrgv Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection can generate a systemic inflammatory response, characterized by a cytokine storm and associated with an exaggerated release of proinflammatory cytokines, including tumor necrosis factor‐α (TNF‐α), interleukin‐6 (IL‐6), and IL‐17, all of which can affect the liver. Here, we aimed to evaluate the cytokine profiles of patients suffering from coronavirus disease (COVID)‐19 and/or hepatitis. We subjected 87 patients to serology and/or polymerase chain reaction analysis for the hepatitis C virus. They were also tested for TNF‐α, IL‐6, and IL‐17 using commercial immunoassay kits. The test results of the COVID‐19/hepatitis C patients (n = 8) were compared with that of the negative controls (n = 28), hepatitis C patients (n = 29), and COVID‐19 patients (n = 22). All COVID‐19 patients (mono‐ and coinfected) expressed high levels of cytokines. The COVID‐19/hepatitis patients exhibited higher levels of IL‐6 (6.33 ± 3.9 pg/ml) and IL‐17 (102.23 ± 2.7 pg/ml); however, TNF‐α values were lower (68.08 ± 15.88 pg/ml), as compared with that of the hepatitis patients (p < 0.001), and lower than that of the COVID‐19 patients and exceptionally for TNF‐α (p < 0.05). These data highlight the importance of monitoring patients with hepatitis and COVID‐19. Organization (2021) mentions that an asymptomatic elevation of the liver enzymes, as detected in 14%−16% of the studied cases, is the most common observation. In fact, in >50% of the patients analyzed, there was an increase in alanine transferase (ALT) and aspartate aminotransferase (AST), along with a significant elevation of gammaglutamyl transferase (GGT). Moreover, there was a slight elevation in the total bilirubin (BT) in 10% of the patients, while the alkaline phosphatase enzyme was typically in the normal range in mild cases of COVID-19. As compared with the severe COVID-19 cases, the liver enzymes were less elevated in the mild cases of the disease, only up to three times the value of the upper normal limit. In fact, among the studied patients, the serum AST levels were >40 IU/L in 52% of the patients who progressed to death and only in 16% of the ones who progressed satisfactorily. In general, changes in AST are more frequent, as compared with the changes in ALT in the severe patients. 4 Incidentally, hepatitis C virus (HCV) infection has a worldwide distribution, but the majority of the individuals infected with HCV remain asymptomatic, that is, they do not develop the acute form of the disease. Moreover, among the small percentage of acute hepatitis C cases, approximately 30% are cured spontaneously within 6 months, while the remaining 70% develop into the chronic form of the disease, which is associated with a high risk of liver cirrhosis and hepatocellular carcinoma. 5 Several theories have been proposed to explain the pathophysiology of SARS-CoV-2 and HCV coinfection. These include the intrinsic tropism of the virus for hepatocytes and bile ducts that may occur as a direct consequence of the complex humoral immune responses in these patients. Alternatively, it may be an indirect response to the cytokine storm, that is, the exaggerated production of proinflammatory cytokines during COVID-19. In fact, the latter theory is highly relevant, and it may be the key factor in the development and evolution of the clinical and laboratory disease profiles for SARS-CoV-2 and HCV coinfection. 6 Recent studies have reported a high production of proinflammatory cytokines in severe clinical cases of SARS-CoV-2 infection; additionally, the increased levels of IL-6, tumor necrosis factor-α (TNF-α), IL17A, IL-10, and interleukin-2 receptor (IL-2R) in patients diagnosed with chronic liver disease may associate the cytokine storm with the severity of COVID-19 in this group of patients. 7 In the present study, we evaluated the immunological profiles of COVID-19 patients, with and without liver changes, as well as patients suffering from only hepatitis C. The enzymatic and immunological profiles of eight patients suffering from both acute COVID-19 and chronic hepatitis C were compared with the corresponding profiles of 28 healthy subjects (i.e., negative for both diseases), 22 patients with acute COVID-19, and 29 patients with chronic hepatitis C. The inclusion criteria for the study were: The SARS-CoV-2 RNA was extracted from nasopharyngeal swab samples (by Qiagen commercial kit) and quantified using TaqMan RT-qPCR assay (AgPath-ID One-Step RT-PCR; Thermo Fisher Scientific). A set of different oligonucleotides and probes were used to detect the SARS-CoV-2 RNA. 8, 9 Descriptive statistical analysis was performed by calculating the means and frequencies of the test results, and the possible relationships between categorical variables were evaluated using χ 2 or Fisher's exact test, whichever was applicable. Statistical significance was set at p < 0.05. Statistical analyses were performed using GraphPad Software Prism (version 9.0). We observed that the liver enzymes of the patients suffering from only hepatitis were higher than the normal reference values but lower than the expected thresholds for chronic HCV infection The authors declare that there are no conflict of interests. This study was approved by Oswaldo Cruz Foundation ethical committee CAAE 30468620.5.0000.5248 approval number 4.112.243. All patients provided written informed consent. Performed the experiments, analyses and interpretation of the data, The data that support the findings of this study are available from the corresponding author upon reasonable request. Clinical characteristics of 2019 novel coronavirus infection in China Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study WGO guidance for the care of patients with COVID-19 and liver disease The natural history of hepatitis C virus (HCV) infection COVID-19 and liver disease: mechanistic and clinical perspective Mechanisms and consequences of COVID-19 associated liver injury: what can we affirm? Disponível em Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Liver enzyme alteration: a guide for clinicians Liver injury in COVID-19: the current evidence Immunopathogenesis and treatment of cytokine storm in COVID-19 Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors Correlation between serum cytokines, interferons and liver functions in hepatitis C virus patients Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality Clinical and laboratory characteristics of hepatitis C and COVID-19 coinfection: prolonged RNA shedding in nonhospitalized cases Survival and outcomes for coinfection of chronic hepatitis C with and without cirrhosis and COVID-19: a multicenter retrospective study COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons Molecular immune pathogenesis and diagnosis of COVID-19 COVID-19: a case for inhibiting IL-17? TNFα inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus